Vancouver, Dec. 18, 2023 (GLOBE NEWSWIRE) -- The global Chemiluminescence Immunoassay (CLIA) analyzers market size was USD 5.42 Billion in 2022 and is expected to register rapid revenue CAGR of 6.0% during the forecast period. The global Chemiluminescence Immunoassay (CLIA) analyzers market is witnessing significant growth, propelled by the increasing prevalence of chronic and acute diseases and advancements in CLIA analyzer technology. These devices play a crucial role in detecting complex formations associated with conditions like endocrine disorders, oncology, infectious diseases, hepatitis, cardiovascular disorders, and more.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/2570
Health Impact and Market Dynamics:
The rise in chronic diseases such as cancer and heart disease is a major driver of market growth. Approximately 10 million deaths globally, one in six, were attributed to cancer in 2020. The ability of CLIA analyzers to precisely diagnose and monitor diseases, including cancer, is aiding in effective treatment strategies. The machines are also contributing to vital research efforts, as showcased in a recent study utilizing CLIA for Alzheimer's disease diagnosis.
Technological Advancements:
Technological progress in CLIA analyzers is enabling the development of faster and more accurate models. High throughput, automation, and connectivity are enhancing the effectiveness of these analyzers. Multiplexing capabilities allow the analysis of multiple analytes in a single sample, reducing the need for independent tests. However, challenges such as the lack of qualified medical professionals and stringent regulations pose obstacles to market growth.
Market Trends:
A notable trend in the market is the introduction of next-generation integrated immunoassays. Companies like Abbott and Danaher are actively involved in research and development projects, expanding their test offerings and gaining regulatory approvals for innovative technologies.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @
https://www.emergenresearch.com/request-discount/2570
Market Segmentation:
Type Insights:
The high throughput segment dominated the market in 2022, owing to its ability to quickly analyse a large number of samples. Abbott Laboratories and Fapon are notable contributors with their high throughput CLIA analysers.
Product Insights:
The reagent segment is expected to witness fast revenue growth due to reduced costs and faster testing times. Roche Diagnostics is a major player offering a diverse range of reagents. Consumables, including stains and chemicals, are in high demand, with companies like Globe Scientific providing quality and cost-effective options.
End-Use Insights:
Hospitals and clinics are anticipated to register moderate revenue growth due to increased hospital visits related to infectious diseases and cancer. Chemiluminescence Immunoassay (CLIA) analyzers are crucial for various tests, such as those for autoimmune diseases, diabetes, thyroid, hepatitis, HIV, and therapeutic medication monitoring.
Regional Insights:
North America:
The North America market held the largest revenue share in 2022, driven by the increasing prevalence of chronic diseases and the presence of key market players like Johnson & Johnson and Abbott Laboratories.
Asia Pacific:
The Asia Pacific market is poised for the fastest revenue growth, attributed to rising awareness about chronic illnesses, patient knowledge about early diagnosis, and increasing disposable income.
Europe:
The Europe market is expected to account for a considerable revenue share, driven by the prevalence of chronic illnesses, the demand for Point-of-Care testing, and the aging population.
Direct Order Can Be Placed Through This Link [Exclusive Copy] @
https://www.emergenresearch.com/select-license/2570
Scope of Research
| Report Details | Outcome |
| Market Size in 2022 | USD 5.42 Billion |
| CAGR (2023–2032) | 6.0 % |
| Revenue Forecast To 2032 | USD 9.7 Billion |
| Base Year For Estimation | 2022 |
| Historical Data | 2019–2021 |
| Forecast Period | 2023–2032 |
| Quantitative Units | Revenue in USD Billion and CAGR in % from 2023 to 2032 |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | type, application, product, end-use, and region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Country Scope | U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Benelux, Russia, Rest of Europe, China, India, Japan, South Korea, ASEAN Countries, Oceania, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, and Rest of Middle East & Africa |
| Key Companies Profiled | F. Hoffmann, La Roche AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Danaher Corporation, Beckman Coulter Inc., DiaSorin S.p.A., Sysmex Corporation, Randox Laboratories Ltd., Tosoh Corporation, Shenzhen New Industries Biomedical Engineering Co., Ltd., bioMerieux SA, Abbott Laboratories, Johnson & Johnson, Ortho Clinical Diagnostics, and Quidel Corporation. |
| Customization Scope | 10 hours of free customization and expert consultation |
Major Companies and Competitive Landscape
The global CLIA analyzers market is fairly fragmented with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective CLIA analyzers solutions. Some major players included in the global CLIA analyzers market report are:
- F. Hoffmann-La Roche AG
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Siemens Healthineers AG
- Danaher Corporation
- Beckman Coulter Inc.
- DiaSorin S.p.A.
- Sysmex Corporation
- Randox Laboratories Ltd.
- Tosoh Corporation
- Shenzhen New Industries Biomedical Engineering Co., Ltd.
- bioMerieux SA
- Abbott Laboratories
- Johnson & Johnson
- Ortho Clinical Diagnostics
- Quidel Corporation
Strategic Development
- In April 2020, Accelerate Diagnostics, Inc. and BioCheck, Inc. signed a strategic distribution agreement for CLIA products. According to the terms of this agreement, Accelerate will set up BioCheck's MS-FAST system, a fully automated CLIA analyzer, and BioCheck's SARS-CoV-2 assays for the detection of IgM and IgG antibodies.
- In December 2020, Siemens Healthineers launched its Atellica solution immunoassay analyzers for high-volume testing in clinical laboratories.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@
https://www.emergenresearch.com/industry-report/chemiluminescence-immunoassay-analyzers-market
Segments Covered in Report
For the purpose of this report, Emergen Research has segmented the global CLIA analyzers market on the basis of type, application, product, end-use, and region:
- Type Outlook (Revenue, USD Billion; 2019-2032)
- High Throughput
- Medium Throughput
- Low Throughput
- Application Outlook (Revenue, USD Billion; 2019-2032)
- Endocrine Disorders
- Oncology
- Infectious Diseases
- Hepatitis and Retrovirus
- Cardiovascular Disorders
- Allergy
- Autoimmunity
- Drug Discovery and Development
- Others
- Product Outlook (Revenue, USD Billion; 2019-2032)
- Analyzers
- Automated
- Semi-automated
- Reagents
- Luminophore Markets
- Enzymatic Markets
- Consumables
- Analyzers
- End-use Outlook (Revenue, USD Billion; 2019-2032)
- Hospitals & Clinics
- Pharmaceutical and Biotechnology Companies
- Others
- Regional Outlook (Revenue, USD Billion; 2019–2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Benelux
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- ASEAN Countries
- Oceania
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- Israel
- Turkey
- South Africa
- Rest of Middle East & Africa
- North America
Curated Reports You Shouldn't Miss: Dive In Now!
Cell Therapy Market by Cell Type (Stem Cells, T Cells, and Others), By Therapy Type (Autologous and Allogeneic), By Technology, By Application, By End-use, and by Region Forecast to 2032
Pet Insurance Market, By Policy Coverage (Accident & Illness, Accident Only, and Embedded Wellness), By Animal Type (Dogs, Cats, and Others), By Service Provider (Private and Public), and By Region Forecast to 2032
Ablation Systems Market, By Device Technology [Radiofrequency (RF) Devices, Ultrasound Devices, and Others], By Application (Cancer, Ophthalmologic, Urological Treatment, and Others), By End-Use, and By Region Forecast to 2032
Cannabidiol (CBD) Oil Market, By Product (Marijuana Based and Hemp Based), By Application [Food & Beverages (F&B), Pharmaceuticals, Pet Care, and Others], By End-Use, and by Region Forecast to 2032
Smart Inhalers Market, By Product (Dry Powder Inhaler and Metered Dose Inhaler), By Disease Indication [Chronic Obstructive Pulmonary Disease (COPD), Asthma, and Others], By Distribution Channel, By End-Use, and by Region Forecast to 2032
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights
